Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Gains from Investment Securities (2016 - 2025)

Conmed (CNMD) has disclosed Gains from Investment Securities for 4 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1.3 million, compared with a TTM value of -$37.5 million through Sep 2025, down 146.71%, and an annual FY2024 reading of -$41.0 million, changed N/A over the prior year.
  • Gains from Investment Securities was $1.3 million for Q3 2025 at Conmed, up from -$1.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.4 million in Q1 2023 and bottomed at -$41.0 million in Q4 2024.
  • Average Gains from Investment Securities over 4 years is -$5.5 million, with a median of -$1.8 million recorded in 2025.
  • The sharpest move saw Gains from Investment Securities plummeted 247.54% in 2024, then skyrocketed 160.53% in 2025.
  • Year by year, Gains from Investment Securities stood at $2.5 million in 2022, then tumbled by 236.46% to -$3.4 million in 2023, then crashed by 1094.64% to -$41.0 million in 2024, then soared by 103.27% to $1.3 million in 2025.
  • Business Quant data shows Gains from Investment Securities for CNMD at $1.3 million in Q3 2025, -$1.8 million in Q2 2025, and $4.0 million in Q1 2025.